Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Infliximab

5

XVII.e Pneumocystis jiroveci pneumonia

1
Last update : 06/04/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Biosimilars
1
Infliximab biosimilar
1
TNF-alpha antagonists / inhibitors
5

Publications

Pneumocystis pneumonia associated with infliximab in Japan.
The New England journal of medicine 2007 Nov 01;357;1874-6 2007 Nov 01
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
Digestive diseases and sciences 2007 Jun;52;1481-4 2007 Jun
Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis.
Internal medicine (Tokyo, Japan) 2006;45;685-8 2006
Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.
Inflammatory bowel diseases 2004 Sep;10;657-60 2004 Sep
Pneumocystis carinii pneumonia following a second infusion of infliximab.
Rheumatology (Oxford, England) 2002 Aug;41;951-2 2002 Aug

Powered by

  • ^
  • Contact
  • Cookies
  • About